---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-078328"
form_type: "8-K"
ticker: "LABT"
cik: "0002079272"
company_name: "Lakewood-Amedex Biotherapeutics Inc."
filed_at: "2026-07-15T20:15:21+00:00"
generated_at: "2026-07-15T20:17:14.333336+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "medium"
source: SEC EDGAR
---

# Lakewood-Amedex releases investor deck on Bisphosphocin platform and Nu-3 gel for diabetic foot ulcers

## Summary
- Investor deck highlights Bisphosphocin® compounds, a novel class of fast-acting, broad-spectrum antimicrobials.
- Lead program Nu-3 is a topically delivered antimicrobial gel for infected diabetic foot ulcers (iDFU).
- Deck includes preclinical/clinical data, regulatory strategy, intellectual property, and competitive landscape.
- Presentation is for use in meetings with investors, analysts, and third parties; no material financial updates.

## SEC filing metadata
- accession: 0001213900-26-078328
- form_type: 8-K
- ticker: LABT
- cik: 0002079272
- company_name: Lakewood-Amedex Biotherapeutics Inc.
- filed_at: 2026-07-15T20:15:21+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: medium
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2079272/000121390026078328/0001213900-26-078328-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2079272/000121390026078328/ea0297963-8k_lakewood.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-078328
- JSON: https://secwatch.observer/filing/0001213900-26-078328.json
- Plain text: https://secwatch.observer/filing/0001213900-26-078328.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.